This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Influenza Vaccination in Children—Costs and Benefits

Influenza Vaccination in Children—Costs and Benefits

Format

Webcast

Time to Complete

1.25 hours

Released

October 25, 2016

Expires

October 25, 2017
Add to Queue


Maximum Credits

1.25 / AMA PRA Category 1 Credit(s)TM

Accredited Provider



This educational activity is provided by Haymarket Medical Education.

Commercial Supporter

Supported by an educational grant from AstraZeneca.

Program Description

This panel discussion focuses on vaccination programs in children against influenza-related morbidity and mortality. The faculty reviews variations in global immunization policy for children in the context of the clinical and economic burden of pediatric influenza infection, including its impact in the wider community. By elucidating the potential benefits and costs of vaccinating children to prevent morbidity and mortality in children and others in the community, including the at-risk elderly, this program will help policymakers, clinicians, and the wider community make decisions regarding implementation of evidence-based interventions for influenza prevention.

Intended Audience

Clinicians, policymakers, and others with an interest in decision making regarding implementation of evidence-based interventions for pediatric influenza management

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Analyze the variations in global public health policy for influenza vaccination in children
  • Describe current trends in influenza morbidity and mortality in children and other age groups
  • Determine the clinical and socioeconomic burden of influenza infection in children and other age groups
  • Advise clinicians, policymakers, and the wider community regarding the implementation of evidence-based interventions for influenza management, including the adoption of novel and emerging influenza vaccines and treatments

Conflict Of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

Faculty

Robert B. Belshe, MD
Professor of Medicine, Emeritus
Saint Louis University School of Medicine
St. Louis, MO, US

Dr. Belshe is a consultant for GlaxoSmithKline, MedImmune, and Sanofi Pasteur and is on the speakers’ bureau for Sanofi Pasteur.

Alistair McGuire, PhD
Professor of Health Economics
London School of Economics
London, UK

Dr. McGuire has no relevant financial relationships to disclose.

Pedro A. Piedra, MD
Professor, Molecular Virology and Microbiology
Baylor College of Medicine
Houston, TX, US

Dr. Piedra is a scientific advisor for AstraZeneca.

Accredited Provider Disclosure

The Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Credit

1.25

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 CreditTM  is generally accepted as equivalent to EACCME credit in Europe, through a reciprocity agreement between the American Medical Association and the European Union of Medical Specialists (UEMS).

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Disclaimer

The opinions expressed in this activity are those of the individual faculty members and do not necessarily reflect those of Haymarket Medical Education or AstraZeneca. Please consult the appropriate package insert for full prescribing information on all drug therapies discussed.

If you have any questions relating to the accreditation of this activity, please contact cmequestions@haymarketmedical.com.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue